<DOC>
	<DOCNO>NCT03078101</DOCNO>
	<brief_summary>This study prospective , clinical pilot study CKD patient show whether Empagliflozin addition ACEi treatment significantly increase Ang 1-7 level compare ACEi treatment alone . Null alternative hypothesis : H0 : Empagliflozin addition ACEi treatment increase Ang 1-7 level ACEi treatment alone . H1 : Empagliflozin addition ACEi treatment significantly increase Ang 1-7 level compare ACEi treatment alone Methodology : Two group 24 chronic kidney disease ( CKD ) patient , respectively , without type 2 diabetes randomize study medication placebo group . The number patient per treatment arm n = 12 . Included consented patient subject initial 2-week run-in period conversion current RAS blocking medication ACEi therapy enalapril ramipril respective dose titration 10 mg enalapril 2 x daily 10 mg ramipril 1 x daily . Additional antihypertensive medication standardize feasible , primary goal keep blood pressure recommend KDIGO . Following 2-week run-in phase , study patient subject blood collection include first RAS quantification ( RAS Fingerprint ) assessment HDL composition , well urinary analysis bioimpedance fluid status assessment ( BCM measurement ) . Subsequently , patient randomize either receive empagliflozin ( dose 10 mg daily ) placebo . Subsequently , biweekly study visit include electrolyte glucose ( plasma urine ) monitoring well BCM measurement take place . After 12 week study medication intake , conclude study visit schedule final RAS quantification ( RAS Fingerprint ) HDL analyse well final blood urinary analysis BCM measurement . Initially , blood urine collect clinical visit part routine blood obtainment ( additional effort patient ) . From routine measurement able extract information regard patient 's current CKD stage well relevant laboratory parameter ( e.g . HbA1c , UACR , etc. ) . Furthermore , document patient 's current medication significant comorbidities . Primary analysis variable/endpoint : The difference Ang 1-7 increase baseline 3-month treatment empagliflozin top ACEi treatment compare ACEi treatment alone Most important secondary analysis variables/endpoints : 1 . Simultaneous quantitative change multiple RAS effector angiotensin level determine mass-spectrometry 2 . Recurrence Ang II level determine mass-spectrometry 3 . HDL parameter ( protein composition HDL ) 4 . Renal parameter ( albuminuria reduction measure urinary albumin-creatinine ratio ( UACR ) , renal function ( estimate glomerular filtration rate ( GFR ) , serum-creatinine ) 5 . Urinary electrolyte level 6 . Urinary glucose level 7 . Urinary RAS metabolite ( angiotensinogen , ACE ACE2 level , ACE2 activity ) 8 . Blood pressure determine ambulatory blood pressure measurements 9 . Body volume determine bioimpedance fluid status assessment ( BCM measurement ) 10 . OCR ECAR PBMCs determine Seahorse Flux Analyzer 11 . Assessment reduction salt sensitivity use salt sensitivity test empagliflozin</brief_summary>
	<brief_title>EMPRA ( EMPagliflozin RAs Kidney Disease )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>CKD patient type 2 diabetes Estimated GFR ( calculate MDRDIDMS formula ) 15 59 ml/min ( CKD stage IIIa/b IV ) Albumin excretion rate 30300 mg/24 hour ( UACR &lt; 300 mg/g ) Fasting plasma glucose level &gt; 126 mg/dl [ 7mmol/L ] HbA1c level &gt; 6.5 % ( Definition type 2 diabetes accord diagnostic criterion set forth American Diabetes Association 2009 ) CKD patient without Diabetes Estimated GFR ( calculate MDRDIDMS formula ) 15 59 ml/min ( CKD stage IIIa/b IV ) Albumin excretion rate 30300 mg/24 hour ( UACR &lt; 300 mg/g ) CKD patient type 2 diabetes Age &lt; 18 year Severely impair renal function ( eGFR &lt; 15ml/min ) Hyperkalemia 4.5mmol/L Hypotension ( systolic blood pressure low 120 mmHg ambulatory measurement ) Pregnant patient Patients plan pregnancy Body mass index &lt; 18.5 kg/m2 CKD patient without diabetes Age &lt; 18 year Diabetic kidney disease Severely impaired renal function ( eGFR &lt; 15ml/min ) Hypotension ( systolic blood pressure low 120 mmHg ambulatory measurement ) Pregnant patient Patients plan pregnancy Body mass index &lt; 18.5 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Empagliflozin</keyword>
	<keyword>SGLT-2 Inhibiton RAS CKD</keyword>
</DOC>